15O-water is the gold standard for quantifying blood flow. We are making it available for routine use.

Most Accurate

Optimal kinetics improves sensitivity specificity

Most Efficient

Higher patient throughput due to short scan time

Safe Production

Scalable in-house production with minimal radiation exposure to patients and staff

NEWS


Vision

MedTrace Pharma A/S was founded with the belief that we can improve diagnostic accuracy in PET perfusion examinations. Our first ambition is to focus on cardiac diseases, and to make 15O-water practically available. We want doctors around the globe to have access to the gold standard perfusion tracer which is 15O-water and to help usher in a new era in diagnostic medicine.

OUR TECHNOLOGY


MedTrace develops a novel solution consisting of hardware and automated analytical software which combined will revolutionize blood flow imaging in PET.

The software solution – aQuant – is a unique analytical platform under development to interpret the 15O-water PET scans. With the aQuant analysis software, MedTrace is developing the world’s first scanner-independent, regulatory approved software offering absolute quantification. Compared to the early days of 15O-water research, aQuant offers clear visual interpretation along with quantitative data of absolute blood flow.

The hardware part of the solution is the MT-100 (under development) that automates bedside production and infusion of 15O-water in the PET scanner suite – just in time for medical demands. The MT-100 will be the world’s first self shielded, GMP-compliant chemistry system for automated production and injection of 15O-water. End of Synthesis is (EoS) is >27 mCi/ml (1G Bq/ml).

The MedTrace solution is a platform technology. Our first priority is the heart exam application (myocardial perfusion imaging), with tumor and brain vascularization studies as well as diabetes applications under development.

Pathway to market

MedTrace is currently preparing for a pivotal Phase III clinical trial evaluating 15O-water PET scans towards invasive coronary angiogram and current best practice SPECT scans. The trial will be conducted under FDA approval and include patients from EU, US and Japan. Several US hospitals are involved coast-to-coast accompanied by three European hospitals and one Japanese.

“The flow of water through the tissues is essentially what makes life possible. All diseases affect the flow of water one way or another. This opens up powerful opportunities of diagnosis using 15O-water and PET”

Professor Jens Soerensen MD PhD, PET Centre, Uppsala University Hospital, Sweden

CLINICAL BENEFITS


REVOLUTIONIZE BLOOD FLOW IMAGING IN PET

Currently, routine myocardial perfusion exams are performed with Tc-99m, Rb-82 and 13N-NH3. The globally recognized gold standard tracer for absolute blood flow measurements is 15O-water (radioactive water), which is used in many clinical studies as the benchmark. The short half-life of radioactive water, the difficult analysis as well as lack of regulatory approved equipment has limited its use in clinical practice so far. With MedTrace’s solution of hardware and analytical software, doctors all over the world will get clinical access to routine use of 15O-water.

THIS WILL ALLOW

Access to gold standard tracer (15O-water) for routine blood flow exams
Faster patient turnaround (2-3 double-tests/hour)
Increased safety for patients and staff
In-house production of the tracers; no 3rd party logistics dependencies.

INDICATIONS OF FUTURE INTEREST

Cardiology
Gold standard for myocardial perfusion

Oncology
Tumor microvasculature

Diabetes
Diabetic foot

Neurology  
Functional bloodflow – Apoplexy, Alzheimer’s

Clinical physiology
Organ blood supply

Tissue perfusion
Ischemic muscle, collateral blood supply

Cardiology
Gold standard for myocardial perfusion

Clinical physiology
Organ blood supply

Tissue perfusion
Ischemic muscle, collateral blood supply

Oncology
Tumor microvasculature

Diabetes
Diabetic foot

Neurology  
Functional bloodflow – Apoplexy, Alzheimer’s

ABOUT MEDTRACE PHARMA


OUR STORY

We are a development stage company innovating PET diagnostic imaging. Having experienced the challenges with false results in myocardial blood flow imaging, we are determined to make the blood flow tracer 15O-water (radioactive water) practically available for clinical use allowing doctors to use the gold standard in the clinic.

OUR PARTNERS

MedTrace collaborates with university hospitals in the US, Europe and Japan as well as global industry partners within nuclear medicine. We are continuously looking for interested clinical, technological and commercial partners globally.

“The availability of a reliable CE approved system for bed-side production of 15O-water could change 15O-water PET from an exotic research tool to a clinical workhorse”

Physicist Lars Poulsen Tolbod, Aarhus University Hospital, Denmark

OUR TEAM


Martin Stenfeldt

Martin Stenfeldt

CEO

Rune Wiik Kristensen

Rune Wiik Kristensen

Chief Operational Officer

Jens Soerensen, MD, Professor

Jens Soerensen, MD, Professor

Chief Medical Officer

Mark Lubberink, Professor

Mark Lubberink, Professor

Chief Scientific Officer

Peter Larsen, PhD

Peter Larsen, PhD

EVP, Hardware Development

Hans Harms, PhD

Hans Harms, PhD

VP, Software Development

Lars Poulsen Tolbod, Ph.D

Lars Poulsen Tolbod, Ph.D

VP New Indications

Kasper Lykkegaard Therkelsen

Kasper Lykkegaard Therkelsen

Student Assistant (split)Usability and Engineering

Janine Sauer

Janine Sauer

Student Assistant (split)Regulatory Affairs

Therese Eilskov Lundmark Jensen

Therese Eilskov Lundmark Jensen

Student Assistant (split)Legal Affairs

Caroline Askheim Trabado

Caroline Askheim Trabado

Student Assistant (split)Project Coordination

Rebekka Stenfeldt

Rebekka Stenfeldt

Student Assistant (split)Commercial Affairs

OUR BOARD OF DIRECTORS


Ulrik Spork

Ulrik Spork

Chairman

Bernt Skou Jensen

Bernt Skou Jensen

Director

Mads Rasmussen

Mads Rasmussen

Vice-chairman

Jens Soerensen, MD, Professor

Jens Soerensen, MD, Professor

Director & CMO

Michael Frank

Michael Frank

Director

OUR INVESTORS


GRANTS AND AWARDS


DTC Award
DTC Award

We are confident that the introduction of the MedTrace solution will be a paradigm shift in diagnostic imaging impacting most known disease areas.

Rune Wiik Kristensen, COO, MedTrace Pharma A/S

REFERENCES


MEDIA

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

TECHNOLOGY

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

SCIENTIFIC

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.


We believe that making 15O-water practically available for clinical use will change the world of perfusion exams.

Want to stay in contact and follow our journey? Follow MedTrace on Facebook, LinkedIn, Twitter and YouTube.

Headquarter (Denmark)

MedTrace Pharma A/S

Diplomvej 381
DK-2800 Kgs. Lyngby

US Office

MedTrace Pharma, Inc.

545 Boylston Street 12th floor
Boston, MA-02116

Swedish Office

MedTrace AB

Hågavägen 322
S-75263 Uppsala

Headquarter (Denmark)

MedTrace Pharma A/S

Diplomvej 381
DK-2800 Kgs. Lyngby

US Office

MedTrace Pharma, Inc.

545 Boylston Street 12th floor
Boston, MA-02116

Swedish Office

MedTrace AB

Hågavägen 322
S-75263 Uppsala

Contact

+45 28 10 41 49 (GMT+1)
+1 (833) 615-4261 (USA)
connect@medtrace.dk

Social

Contact

+45 28 10 41 49 (GMT+1)
+1 (833) 615-4261 (USA)
connect@medtrace.dk

Social